Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update.

By G. Lyman, S. Temin, Stephen B Edge, Lisa A. Newman, Roderick R. Turner, D. Weaver, A. Benson, L. Bosserman, H. Burstein, H. Cody and 4 more. Journal of Clinical Oncology, 2014

1,108 citations recorded by the source corpus.

Subfields: Cancer Research, Pathology and Forensic Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/7651dc7f8e73be39aec686542bdc418de69a8b31

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. M. Akram
2. Mehwish Iqbal
3. L. Provencher
4. M. Daniyal
5. A. Arnaout
6. A. U. Khan
7. Sarah E H Cokenakes
8. L. Gaboury

Citations in the corpus

• Breast Cancer Treatment. (2021, background): “30 The removal of more lymph nodes and adipose tissue of the axilla by ALND is reserved for patients who have positive nodes on SLN biopsy and will have a mastectomy, patients with inflammatory breast cancer (a rare but aggressive cancer that causes redness and swelling of the breast), and patients…”
• Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. (2015, background): “The American Society of Clinical Oncology Clinical Practice Guideline Update Committee considers the current reported FNR of SNB after NAC in patients who present with involved axillary nodes (from 10% to 30%) unacceptable and will take into consideration any new information regarding this specific ”
• Awareness and current knowledge of breast cancer (2017, background): “Little area close to breast tissue and lump are detached, alongside the wire [140, 141].”